PMID- 20548329
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20211020
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Print)
IS  - 1470-269X (Linking)
VI  - 11
IP  - 5
DP  - 2011 Oct
TI  - Gender-related survival differences associated with polymorphic variants of 
      estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer.
PG  - 375-82
LID - 10.1038/tpj.2010.45 [doi]
AB  - Estrogen replacement therapy in women has shown a protective effect on the 
      development of colonic carcinomas. Gender-related differences in the development 
      of colonic carcinomas have also been reported. Estrogen receptor-beta (ERbeta) is 
      expressed in colon carcinomas and has shown prognostic value in colon cancer 
      patients. This study investigated an ERbeta 3' non-coding polymorphism associated 
      with transcriptional activity to determine clinical outcome in patients with 
      metastatic colon cancer. Genomic DNA from 318 metastatic colon cancer patients, 
      177 males and 141 females, were collected from 1992 to 2003. These patients were 
      analyzed for CA repeat polymorphism of the ERbeta gene. Gender-related survival 
      differences were associated with an ERbeta (CA)n repeat polymorphism (P for 
      interaction=0.003, the likelihood ratio test). Female patients with any short<22 
      (CA)n repeat alleles had shorter overall survival (OS) compared with female 
      patients who had both long>/=22 (CA)n repeat alleles. In the male patients, the 
      opposite OS difference was found. This study supports the role of an ERbeta (CA)n 
      repeat polymorphism as a prognostic marker in metastatic colon cancer; however, 
      this prognostic factor had opposite implications based on gender.
FAU - Press, O A
AU  - Press OA
AD  - Division of Medical Oncology, University of Southern California/Norris 
      Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
FAU - Zhang, W
AU  - Zhang W
FAU - Gordon, M A
AU  - Gordon MA
FAU - Yang, D
AU  - Yang D
FAU - Haiman, C A
AU  - Haiman CA
FAU - Azuma, M
AU  - Azuma M
FAU - Iqbal, S
AU  - Iqbal S
FAU - Lenz, H-J
AU  - Lenz HJ
LA  - eng
GR  - P30 CA014089-27/CA/NCI NIH HHS/United States
GR  - K24 CA082754/CA/NCI NIH HHS/United States
GR  - 5 K24CA827540/CA/NCI NIH HHS/United States
GR  - P30 CA014089/CA/NCI NIH HHS/United States
GR  - K24 CA082754-05/CA/NCI NIH HHS/United States
GR  - 5P30CA14089-271/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100615
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Estrogen Receptor beta)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Adult
MH  - Aged
MH  - Carcinoma/*genetics/mortality/secondary
MH  - Colonic Neoplasms/*genetics/mortality/pathology
MH  - Disease-Free Survival
MH  - Estrogen Receptor beta/*genetics/metabolism
MH  - Female
MH  - Gene Expression
MH  - Genetic Association Studies
MH  - Humans
MH  - Male
MH  - Microsatellite Repeats/genetics
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Polymorphism, Genetic
MH  - Prognosis
MH  - Sex Factors
MH  - Treatment Outcome
PMC - PMC2941547
MID - NIHMS201570
EDAT- 2010/06/16 06:00
MHDA- 2012/02/01 06:00
PMCR- 2012/04/01
CRDT- 2010/06/16 06:00
PHST- 2010/06/16 06:00 [entrez]
PHST- 2010/06/16 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - tpj201045 [pii]
AID - 10.1038/tpj.2010.45 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2011 Oct;11(5):375-82. doi: 10.1038/tpj.2010.45. Epub 2010 
      Jun 15.